The Exchange has sought clarification from Nectar Lifesciences Limited for the quarter ended 31-Mar-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Financial results submitted is not as per format prescribed by SEBI The response of the Company is awaited.
NECLIFE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
NSE has asked Nectar Lifesciences to clarify why its financial results for the quarter ended 31 March 2025 were not submitted in the format prescribed by SEBI under Regulation 33 of the Listing Obligations and Disclosure Requirements Regulations, 2015. The company's response to the exchange is still awaited. This is a procedural compliance query and does not indicate any financial irregularity or fraud. Investors should wait for the company's reply to understand if any restatement or correction is required.
This is a routine formatting compliance clarification, not a penalty or investigation, so the immediate impact on shareholders is likely minimal. However, a delayed or unsatisfactory response could lead to further regulatory action or affect the credibility of the reported numbers.